Tyrosine kinase inhibitor NTRC-0652-0 shows promise for the treatment of cholangiocarcinoma Feb. 3, 2022
Beijing Findcure Biosciences divulges new tyrosine-protein kinase receptor UFO inhibitors Feb. 2, 2022
PI3K-delta inhibitors patented by Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical Feb. 2, 2022
Researchers identify COPA as a prognostic marker and therapeutic target in cervical cancer Feb. 1, 2022
RSS